Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation

This study has been completed.
Sponsor:
Information provided by:
Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT01005784
First received: November 13, 2007
Last updated: October 30, 2009
Last verified: October 2009

November 13, 2007
October 30, 2009
June 2005
January 2008   (final data collection date for primary outcome measure)
Luteinizing hormone rise [ Time Frame: 3-14 days (duration of ovarian stimulation) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01005784 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation
Fixed Versus Flexible GnRH Antagonist Initiation

This is a comparison of pregnancy achievement between two GnRH antagonist protocols which differ in the timing of GnRH antagonist initiation.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Subfertility
  • Drug: Cetrorelix (Cetrotide)
    flexible antagonist administration according to specified criteria
    Other Name: Cetrorelix, Cetrotide, Serono
  • Drug: Cetrorelix (Cetrotide)
    fixed antagonist administration on day 6 of ovarian stimulation
    Other Name: Cetrorelix, Cetrotide, Serono
  • Active Comparator: fixed
    Intervention: Drug: Cetrorelix (Cetrotide)
  • Experimental: flexible
    Intervention: Drug: Cetrorelix (Cetrotide)
Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril. 2011 Feb;95(2):558-62. Epub 2010 Jul 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
146
March 2008
January 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • < 39 years of age
  • BMI 18.5-29.9
  • <= 3 previous IVF cycles

Exclusion Criteria:

  • PCOS
  • Endometriosis
Female
18 Years to 39 Years
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
NCT01005784
UHR-3
No
Prof. Basil Tarlatzis, Medical School, Aristotle University of Thessaloniki
Aristotle University Of Thessaloniki
Not Provided
Principal Investigator: Efstratios Kolibianakis Unit for Human Reproduction
Aristotle University Of Thessaloniki
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP